Clinical Trials Results - National Cancer Institute

In English \| En español

Search


	Clinical Trials Search Results

Page Options

E-Mail This Search

Clinical Trial Questions?

Get Help:

1-800-4-CANCER

	Quick Links


	Help Using the NCI Clinical Trials Search Form Educational Materials About Clinical Trials About NCI's Cancer Clinical Trials Registry Dictionary of Cancer Terms NCI Drug Dictionary

View Content for:

Patients
Health Professionals

Display:

Title
Description with: Locations Eligibility
Full Trial Description
Custom

Results 1-25 of 37 for your search:

Drug:  QS21
Find trials that include:  Any drugs shown
Trial Status:  Closed

Hide Search Criteria

Show Search Criteria

Help with Results

Select All on Page Sort by: Show Results per Page

Phase III Randomized Study of Vaccination with Ganglioside GM2 Conjugated to Key Hole Limpet Hemocyanin plus Immunologic Adjuvant QS21 vs High Dose Interferon Alfa-2b in Patients with High Risk Melanoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: E-1694, CAN-NCIC-ME9, MDA-DM-E1694, MSKCC-96008, SWOG-9512, CAN-NCIC-E1694, MSKCC-E1694, SWOG-E1694, E1694, ME9

Phase III Randomized Study of Postoperative GM2-KLH and QS21 Vaccination Versus Observation in Patients With Primary Cutaneous Stage II Melanoma

Phase: Phase III
Type: Treatment
Status: Closed
Age: 18 to 80
Sponsor: Other
Protocol IDs: EORTC-18961, BMS-CA152-003, NCT00005052

Phase I/II Pilot Study of Vaccination with Tyrosinase Peptides or Proteins or Tyrosinase-KLH Conjugate plus QS-21 in High-Risk Stage III/IV Melanoma (Summary Last Modified 06/95)

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: no age specified
Sponsor:
Protocol IDs: MSKCC-94029, NCI-V94-0467

Phase I/II Study of Vaccination with Tumor-Specific CML Breakpoint Peptides plus QS21 for Chronic Myelogenous Leukemia in Partial or Complete Remission (Summary Last Modified 01/1998)

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: over 18
Sponsor: NCI
Protocol IDs: MSKCC-95029A3, NCI-H95-0683

Phase I/II Randomized Study of Vaccination With Melanoma Antigen-Pulsed Dendritic Cells Versus Melanoma Antigens With QS21 Adjuvant in Patients With Surgically Resected Stage IIB, IIC, or III Melanoma

Phase: Phase II, Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NYU-RUH-NBH-0428-0401, RUH-NBH-0428-0401, NCI-5636, NCT00045383, 5636

Phase II Study of Immunization Using Anti-Idiotypic MOAB BEC2 with QS21 Adjuvant in Melanoma Patients Disease-Free Following Surgery But at High Risk of Recurrence (Summary Last Modified 04/94)

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor:
Protocol IDs: MSKCC-93087A1, NCI-V94-0348

Phase II Pilot Study of Booster Vaccinations with GM2-KLH plus QS21 for Stage III/IV Melanoma (Summary Last Modified 03/95)

Phase: Phase II
Type: Treatment
Status: Completed
Age: any age
Sponsor:
Protocol IDs: MSKCC-94009A1, NCI-V94-0458

Phase II Pilot Study of Vaccination with GM2-KLH plus QS21 in Stage III/IV Melanoma (Summary Last Modified 06/95)

Phase: Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor: NCI
Protocol IDs: MSKCC-94041, NCI-H94-0471

Phase II Randomized Study of Vaccination with GM-2 Ganglioside Conjugated to Keyhole Limpet Hemocyanin plus the Immunologic Adjuvant QS21 with vs without High-Dose Interferon alfa in High-Risk Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: E-2696, E2696

10.

Phase II Randomized Study Comparing Immunologic Responses of Stage II and III Colorectal Cancer Patients on Adjuvant Therapy Treated with 3H1 Anti-Idiotype Monoclonal Antibody Mixed with Sargramostim Versus 3H1 Anti-Idiotype Monoclonal Antibody Alum Precipitate Mixed with Sargramostim (Summary Last Modified 01/2000)

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: UKMC-95GI24CB, NCI-H97-1184

11.

Phase II Study of Vaccination with Mucin Peptide (MUC-2) Keyhole Limpet Hemocyanin Conjugate Plus the Immunological Adjuvant Q21 in Patients with Prostate Cancer (Summary Last Modified 02/1999)

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-97122, NCI-G98-1378

12.

Phase II Study of Vaccination with Tn(c)-KLH Conjugate Plus the Immunological Adjuvant QS21 in Patients with Prostate Cancer (Summary Last Modified 05/1999)

Phase: Phase II
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-98002, NCI-G98-1440

13.

Phase II Randomized Study of gp100-Tyrosinase Peptide Vaccine Using Sargramostim (GM-CSF), Montanide ISA-51, or QS21 as Adjuvant in Patients with Advanced Melanoma

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-98012, NCI-T97-0110, NCT00003362, T97-0110

14.

Phase II Study of a Multivalent Tumor-Specific Breakpoint Peptide Vaccine in Patients With Chronic Myelogenous Leukemia

Phase: Phase II
Type: Treatment
Status: Completed
Age: Over 16
Sponsor: NCI
Protocol IDs: MSKCC-99012, NCI-H99-0036, NCT00004052

15.

Phase II Study of Immunization With Polysialic Acid Keyhole Limpet Hemocyanin (PSA-KLH) Conjugate or N-Propionylated PSA-KLH Hemocyanin Conjugate Plus Immunological Adjuvant QS21 in Patients With Small Cell Lung Cancer With Complete or Partial Response to Initial Therapy

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-98065, NCI-H99-0047, NCT00004249

16.

Phase II Study of Vaccination With Glycosylated MUC-2 Antigen With Keyhole Limpet Hemocyanin Conjugate Plus Immunological Adjuvant QS21 in Patients With Progressive Prostate Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-99056, NCI-G00-1697, NCT00004929

17.

Phase II Pilot Study of a Multivalent Conjugate Vaccine With Adjuvant QS21 in Patients With Biochemically Relapsed Prostate Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-00064, NCI-G01-1940, NCT00016120

18.

Phase II Study of Glycosylated MUC-2-Globo H-KLH Conjugate Vaccine With Adjuvant QS21 in Patients With Prostate Cancer

Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: MSKCC-01140, NCI-G02-2064, NCT00036933

19.

Phase II Pilot Study of Vaccination with GM2 Covalently Attached to KLH plus the Immunological Adjuvant QS21 in Patients with Resected Stage III/IV Melanoma (Summary Last Modified 05/92)

Phase: Phase II
Type: Treatment
Status: Closed
Age: any age
Sponsor:
Protocol IDs: MSKCC-91071, NCI-V91-0179

20.

Phase II Pilot Study of Vaccination with Sialyl Tn Antigen Covalently Attached to KLH plus QS21 in High-Risk Resected Colorectal Cancer (Summary Last Modified 07/95)

Phase: Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: MSKCC-92100, NCI-V92-0144

21.

Phase II Pilot Study of Vaccination with GD3 Covalently Attached to KLH plus the Immunological Adjuvant QS21 in Patients with Resected Stage III/IV Melanoma (Summary Last Modified 06/93)

Phase: Phase II
Type: Treatment
Status: Closed
Age: no age specified
Sponsor:
Protocol IDs: MSKCC-92168, NCI-V93-0228

22.

Phase II Pilot Study of Vaccination with GD2 Covalently Attached to KLH plus the Immunological Adjuvant QS21 in Patients with Resected High-Risk Stage III/IV Melanoma (Summary Last Modified 06/93)

Phase: Phase II
Type: Treatment
Status: Completed
Age: no age specified
Sponsor:
Protocol IDs: MSKCC-92169, NCI-V93-0229

23.

Phase I Trial of Vaccination with a Tyrosinase Peptide and Immunologic Adjuvant QS21 in Stage IV Melanoma (Summary Last Modified 02/1999)

Phase: Phase I
Type: Treatment
Status: Closed
Age: over 18
Sponsor: NCI
Protocol IDs: MSKCC-95052, NCI-H95-0769

24.

Phase IB Study of Vaccination with a Recombinant Mutant ras Protein with the Immunologic Adjuvant QS21 in Patients with Adenocarcinomas Expressing an Activated ras Oncoprotein (Summary Last Modified 03/98)

Phase: Phase I
Type: Treatment
Status: Closed
Age: over 18
Sponsor: NCI
Protocol IDs: NCI-97-C-0018, CRB-9411, NCI-NMOB-9608, NCI-T95-0048N, T95-0048

25.

Phase I Pilot Study of Vaccination with Recombinant Mutant ras Peptide with the Immunologic Adjuvant QS21 in Advanced Pancreatic Adenocarcinoma (Summary Last Modified 04/2000)

Phase: Phase I
Type: Treatment
Status: Closed
Age: 18 and over
Sponsor: Other
Protocol IDs: RPCI-DS-94-23, FCCC-98025, NCI-V96-1035

Select All on Page

Help with Results

A Service of the National Cancer Institute